Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Treatment-resistant schizophrenia Indication Strategy Report 2026: M1 receptor, Trials and Deals
24 July 2026
2026 Treatment-resistant schizophrenia strategy: epidemiology, M1 receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Postpartum psychosis Indication Strategy Report 2026: GABA-A receptor, Trials and Deals
24 July 2026
2026 Postpartum psychosis strategy: epidemiology, GABA-A receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Borderline personality disorder Indication Strategy Report 2026: 5-HT2A receptor, Trials and Deals
24 July 2026
2026 Borderline personality disorder strategy: epidemiology, 5-HT2A receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Bulimia nervosa Indication Strategy Report 2026: 5-HT2C receptor, Trials and Deals
24 July 2026
2026 Bulimia nervosa strategy: epidemiology, 5-HT2C receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Moyamoya disease Indication Strategy Report 2026: RNF213, Trials and Deals
24 July 2026
2026 Moyamoya disease strategy: epidemiology, RNF213 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
CARASIL Indication Strategy Report 2026: HTRA1, Trials and Deals
24 July 2026
2026 CARASIL strategy: epidemiology, HTRA1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with PatSnap…
Latest Hotspot
8 min read
CADASIL Indication Strategy Report 2026: NOTCH3, Trials and Deals
24 July 2026
2026 CADASIL strategy: epidemiology, NOTCH3 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with PatSnap…
Latest Hotspot
8 min read
Episodic ataxia type 2 Indication Strategy Report 2026: CACNA1A, Trials and Deals
24 July 2026
2026 Episodic ataxia type 2 strategy: epidemiology, CACNA1A biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Spinocerebellar ataxia type 10 Indication Strategy Report 2026: ATXN10, Trials and Deals
24 July 2026
2026 Spinocerebellar ataxia type 10 strategy: epidemiology, ATXN10 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Spinocerebellar ataxia type 2 Indication Strategy Report 2026: ATXN2, Trials and Deals
24 July 2026
2026 Spinocerebellar ataxia type 2 strategy: epidemiology, ATXN2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
SAPHO syndrome Indication Strategy Report 2026: IL-17A, Trials and Deals
24 July 2026
2026 SAPHO syndrome strategy: epidemiology, IL-17A biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Rasmussen encephalitis Indication Strategy Report 2026: IL-6, Trials and Deals
24 July 2026
2026 Rasmussen encephalitis strategy: epidemiology, IL-6 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…